STELLAR-303 compared zanzalintinib plus atezolizumab with regorafenib in a randomized phase 3 trial. The abstract reports an overall-survival benefit in the overall trial population and more grade 3 or worse treatment-related adverse events. PubMed links a correction that should be reviewed.
Program relevance
Phase 3 STELLAR-303 (NCT05425940) evaluates the exact zanzalintinib–atezolizumab combination in previously treated metastatic colorectal cancer.
Formulation / population: Oral zanzalintinib plus intravenous atezolizumab; not zanzalintinib monotherapy.
PubMed links a published erratum: PMID 41241514. Review the correction before interpreting results.
Journal Article / Randomized Controlled Trial / Clinical Trial, Phase III / Multicenter Study / Comparative Study / Research Support, Non-U.S. Gov't
This publication describes the design and rationale of STELLAR-303, comparing zanzalintinib plus atezolizumab with regorafenib in previously treated metastatic colorectal cancer. It is a protocol publication, not a report of treatment outcomes.
Program relevance
The protocol describes the same STELLAR-303 combination trial; it is not an independent results study.
Formulation / population: Zanzalintinib plus atezolizumab in the same STELLAR-303 program as the results paper.
Trial protocol; not a results publication.
Do not count the protocol and results paper as independent trials.
Source metadata only: PubMed identifies a published correction and supplies no abstract. The correction text was not retrieved; no corrected values are asserted here.
Program relevance
PubMed links this published erratum to the STELLAR-303 results paper, PMID 41130252.
Formulation / population: Correction associated with the zanzalintinib–atezolizumab STELLAR-303 report.